Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients

被引：89
作者：
Rejdak, K
Bartosik-Psujek, H
Dobosz, B
Kocki, T
Grieb, P
Giovannoni, G
Turski, WA
Stelmasiak, Z
机构：
[1] Med Univ, Dept Neurol, PL-20090 Lublin, Poland
[2] Med Univ, Dept Pharmacol, PL-20090 Lublin, Poland
[3] Inst Agr Med, Dept Toxicol, Lublin, Poland
[4] Polish Acad Sci, Lab Expt Pharmacol, Med Res Ctr, Warsaw, Poland
[5] Inst Neurol, Neuroimmunol Unit, London WC1N 3BG, England
来源：
NEUROSCIENCE LETTERS | 2002年 / 331卷 / 01期
关键词：
kynurenic acid; cerebrospinal fluid; multiple sclerosis; human;
D O I：
10.1016/S0304-3940(02)00710-3
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
The present study was undertaken to measure cerebrospinal fluid (CSF) levels of kynurenic acid (KYNA) in patients with relapsing-onset multiple sclerosis (MS) during remission or not progressing for at least 2 months. In these patients the levels of CSF KYNA were found to be significantly lower compared with subjects with non-inflammatory neurological diseases, as well as those with inflammatory disease (median (interquartile range): 0.41 (0.3-0.5) pmol/ml, n = 26 vs. 0.67 (0.5-1.1), n = 23, P < 0.01 and 1.7 (1.5-2.6), n = 16, P < 0.001, respectively). These results provide further evidence of the alterations in the kynurenine pathway during remitting-onset MS. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码：63 / 65
页数：3
相关论文
共 16 条
[1]   CEREBROSPINAL-FLUID IN THE DIAGNOSIS OF MULTIPLE-SCLEROSIS - A CONSENSUS REPORT [J].
ANDERSSON, M ;
ALVAREZCERMENO, J ;
BERNARDI, G ;
COGATO, I ;
FREDMAN, P ;
FREDERIKSEN, J ;
FREDRIKSON, S ;
GALLO, P ;
GRIMALDI, LM ;
GRONNING, M ;
KEIR, G ;
LAMERS, K ;
LINK, H ;
MAGALHAES, A ;
MASSARO, AR ;
OHMAN, S ;
REIBER, H ;
RONNBACK, L ;
SCHLUEP, M ;
SCHULLER, E ;
SINDIC, CJM ;
THOMPSON, EJ ;
TROJANO, M ;
WURSTER, U .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1994, 57 (08) :897-902
[2]  
BARAN H, 2000, SOC NEUR 30 ANN M AB, P1302
[3]   Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS [J].
Blinkenberg, M ;
Rune, K ;
Jensen, CV ;
Ravnborg, M ;
Kyllingsbæk, S ;
Holm, S ;
Paulson, OB ;
Sorensen, PS .
NEUROLOGY, 2000, 54 (03) :558-564
[4]   Oligodendrocyte killing by quinolinic acid in vitro [J].
Cammer, W .
BRAIN RESEARCH, 2001, 896 (1-2) :157-160
[5]   Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis [J].
Chiarugi, A ;
Cozzi, A ;
Ballerini, C ;
Massacesi, L ;
Moroni, F .
NEUROSCIENCE, 2001, 102 (03) :687-695
[6]   A MECHANISM OF QUINOLINIC ACID FORMATION BY BRAIN IN INFLAMMATORY NEUROLOGICAL DISEASE - ATTENUATION OF SYNTHESIS FROM L-TRYPTOPHAN BY 6-CHLOROTRYPTOPHAN AND 4-CHLORO-3-HYDROXYANTHRANILATE [J].
HEYES, MP ;
SAITO, K ;
MAJOR, EO ;
MILSTIEN, S ;
MARKEY, SP ;
VICKERS, JH .
BRAIN, 1993, 116 :1425-1450
[7]   Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types [J].
Heyes, MP ;
Chen, CY ;
Major, EO ;
Saito, K .
BIOCHEMICAL JOURNAL, 1997, 326 :351-356
[8]   Metabolic control of kynurenic acid formation in the rat brain [J].
Hodgkins, PS ;
Schwarcz, R .
DEVELOPMENTAL NEUROSCIENCE, 1998, 20 (4-5) :408-416
[9]  
Kepplinger B, 2001, MULT SCLER S1, V7, pS118
[10]   Amino acid concentrations in cerebrospinal fluid of patients with multiple sclerosis [J].
Klivenyi, P ;
Kekesi, K ;
Juhasz, G ;
Vecsei, L .
ACTA NEUROLOGICA SCANDINAVICA, 1997, 95 (02) :96-98
12